von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

OBJECTIVE--To evaluate as predictors of reinfarction and mortality tissue plasminogen activator antigen and activity before and after venous occlusion, plasminogen activator inhibitor, von Willebrand factor, and established risk factors. DESIGN--Prospective study with a mean observation time of 4.9 years. SETTING--Secondary referral centre, the Department of Internal Medicine, University Hospital of Umeå. PATIENTS--123 consecutive survivors of myocardial infarction under the age of 70 years. MAIN OUTCOME MEASURES--Reinfarction and deaths from all causes. RESULTS--23 patients died and 36 patients had at least one reinfarction. High concentrations of von Willebrand factor were independently associated with both reinfarction and mortality. A history of angina at entry into the study was also independently associated with reinfarction and mortality. Hypertension was independently associated with mortality but not with reinfarction. None of the fibrinolytic or lipid variables was associated with reinfarction or death. CONCLUSION--A high concentration of von Willebrand factor was a novel index of increased risk for reinfarction and mortality in survivors of myocardial infarction.

[1]  J. Jansson,et al.  Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. , 1991, European heart journal.

[2]  A. Blann.  Increased circulating levels of von Willebrand factor antigen in smokers may be due to lipid peroxides , 1991 .

[3]  G. Diamond,et al.  Exercise thallium-201 scintigraphy in the diagnosis and prognosis of coronary artery disease. , 1990, Annals of internal medicine.

[4]  P. Rentrop,et al.  Impaired Fibrinolytic Capacity and Tissue Plasminogen Activator Release in Patients with Restenosis after Percutaneous Transluminal Coronary Angioplasty (PTCA) , 1989, Thrombosis and Haemostasis.

[5]  B. Brenner,et al.  Von Willebrand Factor Multimer Patterns in Pregnancy-Induced Hypertension , 1989, Thrombosis and Haemostasis.

[6]  A. Hamsten,et al.  Correlation between plasma levels of growth factors and von Willebrand factor. , 1989, Thrombosis research.

[7]  G. Dahlén,et al.  Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. , 1989, European heart journal.

[8]  F. España,et al.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. , 1988, British heart journal.

[9]  S. Rahimtoola,et al.  Impaired fibrinolysis in coronary artery disease. , 1988, American heart journal.

[10]  S. Thompson,et al.  Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. , 1988, British heart journal.

[11]  S. Moiseev.  [The role of hemostasis and rheologic properties of blood in stable and progressive exertion-induced stenocardia]. , 1988, Kardiologiia.

[12]  T. Nilsson,et al.  The extrinsic fibrinolytic system in survivors of myocardial infarction. , 1987, Thrombosis research.

[13]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[14]  M. Cohen,et al.  Impaired coronary vasodilator responsiveness as a cause of lactate production during pacing-induced ischemia in patients with angina pectoris and normal coronary arteries. , 1987, Journal of the American College of Cardiology.

[15]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[16]  U. Hedner,et al.  Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis. , 1986, Acta chirurgica Scandinavica.

[17]  M. Blombäck,et al.  Haemostatic function in myocardial infarction. , 1986, British heart journal.

[18]  インターグループ.  SAS user's guide : basics , 1986 .

[19]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[20]  D. Wagner,et al.  Biosynthesis of von Willebrand protein by human megakaryocytes. , 1985, The Journal of clinical investigation.

[21]  Y. Asada,et al.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. , 1985, Thrombosis research.

[22]  E. Raftery,et al.  Haemostatic Variables and the Outcome of Myocardial Infarction , 1983, Thrombosis and Haemostasis.

[23]  K. Mettinger.  A study of hemostasis in ischemic cerebrovascular disease. I. Abnormalities in factor VIII and antithrombin. , 1982, Thrombosis research.

[24]  M. Blombäck,et al.  Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease. , 2009, Acta medica Scandinavica.

[25]  Y. Sultan,et al.  Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage. , 1979, The Journal of laboratory and clinical medicine.

[26]  Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. , 1979, Circulation.

[27]  M. Abbal,et al.  FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE , 1975, The Lancet.

[28]  E. Jaffe,et al.  Synthesis of von Willebrand factor by cultured human endothelial cells. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[29]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .